Sulfated Polysaccharides Effectively Inhibit SARS-Cov-2 In Vitro
To this end, we suggest that treatment of fucoidans, nebulized heparin, or possibly TriS-heparin in combination with or without current antiviral therapies, should be assessed first in human primary epithelial cells and then in human patients suffering from COVID-19.
